N-(2,6-dichlorophenyl)-N'-3-pyridinyl urea | 97627-18-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2,6-dichlorophenyl)-N'-3-pyridinyl urea
• 英文别名: 1-(2,6-dichlorophenyl)-3-pyridin-3-ylurea
• CAS: 97627-18-4
• 化学式: C₁₂H₉Cl₂N₃O
• 分子量: 282.129
• InChiKey: LCVQWTZZWZTSCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  3-氨基吡啶 、 2,6-二氯苯基异氰酸酯 以 四氢呋喃 为溶剂， 以72%的产率得到N-(2,6-dichlorophenyl)-N'-3-pyridinyl urea
  参考文献：
  名称：

  N-Phenyl-N'-pyridinylureas as anticonvulsant agents

  摘要：

  A series of N-phenyl-N'-pyridinylureas was examined for anticonvulsant activity. Extensive structure/activity investigations revealed optimal activity in the N-(2,6-disubstituted-phenyl)-N'-(4-pyridinyl)urea series, with 37 exhibiting the best overall anticonvulsant profile. Compound 37 was effective against seizures induced by maximal electroshock but did not protect mice from clonic seizures produced by the convulsant pentylenetetrazol. The overall pharmacological profile suggests that 37 would be of therapeutic use in the treatment of generalized tonic-clonic and partial seizures. Compound 37 was selected for Phase 1 clinical trials.

  DOI：

  10.1021/jm00164a061

文献信息

• N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas, processes for their production and pharmaceutical compositions comprising the same
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0135335A2

  公开（公告）日：1985-03-27

  N-2,6-Disubstituted phenyl(-N'-3- and 4-pyridinyl ureas having the following general formula are disclosed: A is a 3- or 4-pyridinyl radical; and R', R2 and R3 are independently chosen from a halogen atom, a lower alkyl radical, a lower alkoxy radical, a lower alkanoyl radical, a lower alkoxy carbonyl radical or a nitro group, with R3 additionally being chosen from a hydrogen atom. Processes for producing the compounds, pharmaceutical compositions compnsing the same, and pharmaceutically acceptable acid addition salts thereof are also disclosed. The compounds have anti-convulsant activity and are useful in the treatment of epilepsy.

  本发明公开了具有以下通式的 N-2，6-二取代苯基（-N'-3-和 4-吡啶基）脲： A是3-或4-吡啶基；R'、R2和R3独立地选自卤素原子、低级烷基、低级烷氧基、低级烷酰基、低级烷氧基羰基或硝基，R3另外选自氢原子。此外，还公开了这些化合物的生产工艺、包含这些化合物的药物组合物及其药学上可接受的酸加成盐。这些化合物具有抗惊厥活性，可用于治疗癫痫。
• US4629731A
  申请人：——

  公开号：US4629731A

  公开（公告）日：1986-12-16
• US4962116A
  申请人：——

  公开号：US4962116A

  公开（公告）日：1990-10-09
• US6133299A
  申请人：——

  公开号：US6133299A

  公开（公告）日：2000-10-17
• [EN] METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS USING N-(2,6-DISUBSTITUTED AROMATIC)-N'-PYRIDINYL UREAS AND OTHER ANTICONVULSANT COMPOUNDS<br/>[FR] PROCEDES PERMETTANT DE TRAITER DES MALADIES ET TROUBLES NEURODEGENERATIFS AVEC DES UREES N-(2,6-AROMATIQUES DISUBSTITUES)-N'-PYRIDINYLE ET D'AUTRES COMPOSES ANTICONVULSIVANTS
  申请人：——

  公开号：WO1994018972A2

  公开（公告）日：1994-09-01

  [EN] The instant invention is novel uses of known N-(2,6-disubstituted phenyl)-N'-3- and 4-pyridinyl ureas and pharmaceutically acceptable acid addition salts thereof. Such compounds as N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea monohydrochloride or N-(2,3-dichlorophenyl)-N'-4-pyridinyl urea are used for treating neurodegenerative disorders, perinatal asphyxia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis. The instant invention is similar novel uses of known anticonvulsant compounds as ralitoline, phenytoin, lamotrigine, tetrodotoxin, lidocaine, and carbamazepine.
  [FR] L'invention porte sur des utilisations nouvelles d'urées N-(2,6-phényle disubstitué)-N'-3- et 4-pyridinyle déjà connues et sur leurs sels d'addition d'acide pharmaceutiquement acceptables. Des composés tels que le monohydrochlorure d'urée N-(2-chloro-6-méthylphényle)-N'-4-pyridinyle ou l'urée N-(2,3 dichlorophényle)-N'-4-pyridinyle sont utilisés pour traiter des troubles neurodégénératifs, l'asphyxie périnatale, la maladie d'Alzheimer, la chorée de Huntington, la maladie de Parkinson et la sclérose latérale amyotrophique. L'invention porte aussi sur les mêmes utilisations nouvelles de comopsés anticonvulsivants connus tels que ralitoline, phénytoïne, lamotrigine, tétrodotoxine, lidocaïne et carbamazépine.